A study conducted between September 2021 and August 2022 tested the efficacy and safety of an injectable HIV treatment compared to oral therapy. The injectable group experienced more severe adverse events (nine percent) than the oral group (four percent). Despite this, the injectable regimen showed non-inferior efficacy, offering a viable alternative for those who struggle with daily pill adherence, particularly in African settings where stigma and logistical challenges are significant. The study, titled “Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES),” was published in The Lancet Infectious Diseases journal. The research involved Kenyan scientists, including Prof. Reena Shah of Aga Khan University Hospital, Nairobi, Abraham Siika and Charity Wambui of Moi University, and Josphat Kosgei of the Kenya Medical Research Institute. The World Health Organisation licensed the injectables in 2020 after positive results from studies in Europe, the Americas, and Asia.